Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Alia C. Lynch"'
Autor:
Alissa J. Cooper, MD, Natasha Rekhtman, MD, PhD, Marina K. Baine, MD, PhD, Marie C. Thomas, DNP, FNP-C, Alia C. Lynch, PharmD, BCOP, Ryan D. Gentzler, MD, MS
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100750- (2024)
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-exp
Externí odkaz:
https://doaj.org/article/a8288d90bce449ed811d1abf0dde896c
Publikováno v:
Clinical Case Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary tod
Externí odkaz:
https://doaj.org/article/30dda62953584aa38fff2b90a398fca4
Autor:
Lindsey B. Shantzer, Sean C. Dougherty, Fabian Bolte, John W. Melson, Daniel R. Reed, Alia C. Lynch, Ryan D. Gentzler, Wendy Novicoff, Richard D. Hall
Publikováno v:
Clinical Lung Cancer. 24:e60-e64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d9b4e8d2cce399373879162f1b7db18
https://doi.org/10.1016/j.cllc.2022.11.006
https://doi.org/10.1016/j.cllc.2022.11.006
Autor:
Dougherty, Sean C.1 RDH3Q@hscmail.mcc.virginia.edu, PharmD, Alia C. Lynch2, Hall, Richard D.1
Publikováno v:
Clinical Case Reports. Jun2021, Vol. 9 Issue 6, Special section p1-4. 4p.
Publikováno v:
Clinical Case Reports
Clinical Case Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Clinical Case Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0b1269a69248c7c1ba9f74d4b4c43d9
https://doi.org/10.1002/ccr3.4227
https://doi.org/10.1002/ccr3.4227
Autor:
Alia C. Lynch, Thomas E Schultz
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:993-997
Methotrexate is a dihydrofolate reductase inhibitor that interferes with DNA synthesis, DNA repair, and cellular replication. We present the first adult case of a patient who received intravenous contrast prior to administration of high-dose methotre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f346a4dd41b9d9639851f8aaa76120a
https://doi.org/10.1177/1078155218769126
https://doi.org/10.1177/1078155218769126
Autor:
Edward B. Stelow, Erin M. McLoughlin, James M. Larner, Kevin Brady, Michael P. Bergman, Ryan D. Gentzler, Alia C. Lynch, Ralph Sumner Abraham
Publikováno v:
Journal of Thoracic Oncology. 14:e193-e195
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f18efbeab36516dcf807416128a5ee5
https://doi.org/10.1016/j.jtho.2019.04.010
https://doi.org/10.1016/j.jtho.2019.04.010
Autor:
Wendy Novicoff, Ryan D. Gentzler, Sean C. Dougherty, Alia C. Lynch, Lindsey Shantzer, R. Hall, Daniel R Reed, John Melson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune checkpoint inhibitors (ICIs) have become the backbone of treatment for most driver-mutation negative, advanced non-small cell lung cancers. ICIs have been approved both as monotherapy and in combination with chemotherapy for front li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c78bab1d11334e4cea0d672ab1ef1516
https://doi.org/10.1136/jitc-2021-sitc2021.803
https://doi.org/10.1136/jitc-2021-sitc2021.803